S1207 An Upcoming Trial for High-Risk Breast Cancer - SWOG
S1207 An Upcoming Trial for High-Risk Breast Cancer - SWOG
S1207 An Upcoming Trial for High-Risk Breast Cancer - SWOG
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
4/22/2013<br />
BOLERO‐2<br />
• Addition of everolimus to exemestane prolongs<br />
PFS in patients with ER+ HER2‐ breast cancer<br />
refractory to nonsteroidal aromatase inhibitors.<br />
◦ Local: median 7.4 vs. 3.2 months (HR = 0.44, P < 1 x 10 ‐16)<br />
◦ Central: median 11.0 vs. 4.1 months (HR = 0.36, P < 1 x 10 ‐16)<br />
• Benefit is observed in all subgroups.<br />
• QOL was similar in the two arms.<br />
• Adverse events were consistent with previous<br />
experience with everolimus.<br />
10<br />
Benefit of Systemic Therapy- Ox<strong>for</strong>d Overview<br />
Ox<strong>for</strong>d Overview, 2006<br />
<strong>S1207</strong> Background<br />
• Abnormalities of the PI3kinase/AKT/mTOR<br />
signaling network are some of the most<br />
common molecular anomalies in breast cancer.<br />
• This pathway has been associated with<br />
resistance to endocrine therapies among HRpositive<br />
breast tumors.<br />
• Everolimus, an mTOR-inhibitor, has been<br />
shown to increase the biological activity of<br />
aromatase inhibitors.<br />
4
Change language